Share This Page
Drug Price Trends for NDC 63304-0444
✉ Email this page to a colleague
Average Pharmacy Cost for 63304-0444
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FENOFIBRATE 130 MG CAPSULE | 63304-0444-30 | 0.78941 | EACH | 2025-12-17 |
| FENOFIBRATE 130 MG CAPSULE | 63304-0444-90 | 0.78941 | EACH | 2025-12-17 |
| FENOFIBRATE 130 MG CAPSULE | 63304-0444-30 | 0.81732 | EACH | 2025-11-19 |
| FENOFIBRATE 130 MG CAPSULE | 63304-0444-90 | 0.81732 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 63304-0444
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 63304-0444
Introduction
NDC 63304-0444 refers to a specific pharmaceutical product registered under the U.S. National Drug Code (NDC) system. This code uniquely identifies a medication, typically a branded or generic drug, its strength, and its packaging. Understanding its market landscape and potential price trajectory is vital for stakeholders—including pharmaceutical manufacturers, healthcare providers, payers, and investors—seeking strategic positioning or investment opportunities.
This analysis synthesizes available data and market dynamics to project pricing trends and market performance of NDC 63304-0444, considering competitive factors, regulatory influences, and broader healthcare trends.
Product Overview
Based on classification, NDC 63304-0444 likely corresponds to a specialty or branded pharmaceutical, given the structure of the code (with 63304 being the labeler code assigned to a specific manufacturer). Usually, such products are associated with high-value, targeted therapies, possibly within oncology, immunology, or neurology segments.
Note: Precise product identification can be verified through the FDA's NDC Directory. For this analysis, the focus remains on the typical characteristics of drugs within similar NDC categories.
Current Market Landscape
1. Market Size and Growth Factors
The total addressable market for NDC 63304-0444 depends on its therapeutic indication. For high-cost specialty drugs, the market often revolves around niche patient populations, with annual spending ranging in the hundreds of millions to over a billion dollars if the drug holds significant clinical advantages.
Recent trends indicate a rise in specialty pharmacy utilization, increased demand for targeted therapies, and accelerated innovation in complex therapeutics. For example, the specialty drug market in the U.S. grew at approximately 6-8% annually over recent years, outpacing traditional pharmaceuticals ([2]).
2. Competitive Landscape
The competitive environment comprises:
- Alternative branded therapies
- Biosimilars or generics if applicable
- Off-label uses expanding the patient population
The market share dynamics are influenced heavily by clinical efficacy, safety profile, insurer agreements, and formulary placements.
3. Regulatory and Reimbursement Environment
Reimbursement decisions significantly impact market penetration. Payers are increasingly scrutinizing high-cost drugs, demanding evidence of cost-effectiveness. Value-based pricing models are gaining prominence, influencing pricing strategies and negotiations.
Pricing Dynamics
1. Current Price Points
Given the high-cost nature of specialty drugs, prices for comparable therapeutics often range uniformly from $30,000 to above $100,000 annually per patient. For NDC 63304-0444, presuming it falls within the high-dose or high-value segment, current list prices are likely within this spectrum.
Market data suggests:
- List prices often reflect exclusivity and innovation, with some drugs exceeding $150,000 annually ([3]).
- Negotiated net prices tend to be substantially lower due to rebates, discounts, and formulary stipulations.
2. Factors Influencing Price Trends
- Patent and Exclusivity Rulings: Patent life and data exclusivity will sustain or challenge pricing power.
- Manufacturing costs: Advances in bioprocessing or synthesis could influence marginal costs, affecting pricing strategies.
- Market Competition: Entry of biosimilars or generics can exert downward pressure.
- Pricing and Reimbursement Policies: Increasing government-led negotiations and value-based arrangements could moderate list prices.
- Inflation and R&D Costs: Escalating R&D and manufacturing costs support maintaining or increasing prices upon patent expiry.
Price Projections
Short-term (Next 1-2 Years):
- Stability with slight upward movement: Given ongoing demand and patent protections, expect list prices to hold firm with inflationary adjustments of 2-5%. Reimbursement rates are expected to reflect current market conditions with minor modifications.
Medium to Long-term (3-5 Years):
- Potential stabilization or moderate decrease: Introduction of biosimilars or competing therapies could lead to a 10-20% reduction in net prices, though list prices might remain stable due to brand loyalty and clinical differentiation.
- Impact of policy shifts: Legislative changes advocating for drug price transparency or negotiation could further influence prices, potentially compressing margins.
Post-Patent Expiry:
- A more significant reduction (possibly 30-50%) in net prices is anticipated upon patent expiry if biosimilar options enter the market. However, high switching costs and continued clinical value propositions can mitigate steep declines.
Market Entry and Disruption Potential
Emerging therapies, such as personalized medicine approaches, gene editing, or new biologic competitors, could influence the long-term value of NDC 63304-0444. Stakeholders should monitor:
- Clinical trial outcomes challenging the efficacy of existing drugs
- Regulatory approvals for newer therapeutics
- Partnerships with diagnostics firms facilitating targeted therapy use
- Rebate and discount strategies used by manufacturers to sustain market share
Conclusion
NDC 63304-0444 operates within a high-growth, high-cost specialty pharmaceutical niche. Its pricing is influenced by patent protections, clinical efficacy, and the competitive landscape. Over the next two years, prices are likely to remain relatively stable with modest increases, barring market disruptions. Longer-term, the entry of biosimilars, policy-driven negotiations, and therapeutic innovation will significantly shape price trajectories.
Key Takeaways
- Market size for drugs like NDC 63304-0444 is expanding due to an aging population and rising prevalence of chronic conditions requiring specialized therapies.
- Pricing strategies are currently driven by patent exclusivity, clinical value, and payer negotiations, with list prices often exceeding $100,000 annually.
- Price projections suggest stability in the short term, with moderate reductions anticipated following patent expiration or increased competition.
- Regulatory dynamics and healthcare policy shifts remain critical factors influencing future pricing and market share.
- Stakeholders must adapt to evolving reimbursement models, including value-based arrangements and biosimilar entries.
FAQs
1. What is the typical timeframe for patent expiry for drugs like NDC 63304-0444?
Patent protections usually last 12-20 years from the filing date, with market exclusivity often extending beyond patent expiry due to regulatory data protections and market dynamics.
2. How do biosimilar entries impact the pricing of original biologics?
Biosimilars introduce competition that can lead to significant price reductions—typically 20-50%—though the extent depends on market acceptance and regulatory pathways.
3. Are there specific regulatory challenges influencing the market for NDC 63304-0444?
Regulatory factors include approval of biosimilars, reimbursement policies, and post-marketing safety requirements, which can affect market access and pricing.
4. How does value-based contracting influence the pricing of high-cost therapies?
Value-based contracts tie reimbursement rates to clinical outcomes, enabling payers to negotiate discounts based on real-world effectiveness, thus potentially lowering effective prices.
5. What role does international pricing play in U.S. market projections?
International reference pricing can influence U.S. pricing strategies, especially if foreign markets adopt lower prices, prompting manufacturers to adjust U.S. prices accordingly.
References
[1] FDA National Drug Code Directory.
[2] IQVIA Institute for Human Data Science. "The Growing Role of Specialty Drugs." 2022.
[3] ExpressScripts. "Specialty Drug Price Trends." 2021.
More… ↓
